Gold and Silver Hit New Highs; NVIDIA's GB300 Shipments Expected to Reach 55,000 Units Next Year

Stock News
12/23

**Key Highlights** China's Ministry of Finance and other departments issued guidelines to clarify the definition of domestically produced goods under government procurement policies. Products manufactured in bonded zones or special customs areas qualify as domestically produced, while medical devices must obtain regulatory approval.

**Market Overview** Global gold and silver prices surged to record highs. COMEX gold futures rose 2.13% to $4,480.6/oz, while silver futures climbed 2.37% to $69.09/oz. U.S. stocks posted gains, with the Dow Jones up 0.47%, the S&P 500 up 0.64%, and the Nasdaq up 0.52%. Tech stocks were mixed, with Micron Technology hitting an all-time high (+4%), while NVIDIA and Tesla rose over 1%. Commercial space stocks rallied, with Rocket Lab surging 10% for a three-day cumulative gain of 44%.

**Sector Focus** - **Pharma & E-Commerce**: New regulations for online drug and medical device information services took effect, impacting Hong Kong-listed healthcare platforms. - **Commodities**: Hong Kong’s Financial Secretary Chen Maobo highlighted the city’s potential in global commodity markets, citing China’s role as a major consumer. A gold central clearing system is set for trial in 2026, with storage capacity expanding to 1,000 metric tons. - **Tech**: NVIDIA’s GB300 AI server shipments are projected to grow 129% YoY to 55,000 units in 2026, driven by demand from Microsoft and Meta. The next-gen Vera Rubin 200 platform is slated for Q4 2026 release, benefiting suppliers like Foxconn and Quanta.

**Corporate Updates** - **CTG DUTY-FREE (01880)**: Sales surged 61% YoY on the first day of Hainan’s duty-free island policy, with 1.61 billion yuan ($225M) in purchases. - **NuoBiKan (02635)**: Shares soared 275% in gray-market trading ahead of its Hong Kong debut. - **Others**: CGN Power (01816) adjusted operational timelines for its Huizhou nuclear units, while Sihuan Pharma (02256) secured NMPA approval for its CSF-1R inhibitor.

**Earnings Spotlight** Sanhua Intelligent Controls (02050) forecasted a 25–50% rise in 2025 net profit, citing strong operational performance.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10